Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
UroGen
Pharma
FDA signs off on UroGen's Zusduri after advisory committee snub
Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Zoey Becker
Jun 13, 2025 8:56am
FDA to host first oncology adcomm meeting under Makary
May 8, 2025 11:35am
UroGen: This year 'critical for Jelmyto's success'
Mar 24, 2022 8:50am
UroGen undeterred after RTGel-Botox combo misses in phase 2
Sep 3, 2020 10:15am
UroGen gears up virtual launch as FDA clears Jelmyto chemo gel
Apr 16, 2020 11:36am
